Doug's Daily Diary

Out With the Gold...

Jim Cramer's Latest Post

Options Profits/AAO

Technical Corner

Featured Commentary

More Trading Strategies

How to Play Gold With G-20 Looming

In a more complex trade I would want to be long some sort of ratio risk reversal.

Grub Hub is Becoming More Appetizing

Chart patterns suggest food delivery service company has bottomed out and may be turning.

At This Price, General Mills Is Not the Pick of Champions

But with indicators mixed, traders could approach the long side of GIS if they use a sell stop below $51.

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Despite the financial positivity, many analysts warn the deal could have hiccups ahead.

AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere

The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.

Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015

PFE was ready to pay $160 billion until U.S. regulators blocked the deal.

Analysts Seem to Expect Further Disappointments From FedEx - Charts Not So Much

Let's look at their price charts and technical indicators, and draw some conclusions.

Selling Rotates Into Larger-Cap Names

Meanwhile, the latest economic data suggest the likelihood of a Fed rate cut at the next FOMC meeting.

Buffett Should Look at Kraft Heinz's Charts, Too, When Pondering His Investment

Shares of the food giant may not have made a bottom, but it will be interesting to see how the stock behaves from here.

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.